Results 121 to 130 of about 1,308 (153)

A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers

Current Medicinal Chemistry, 2012
Fabry disease is an X-linked, multisystemic lysosomal storage disorder due to alpha-galactosidase A deficiency. It is characterized by the accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in biological fluids, vascular endothelium, heart, and kidneys.
F O, Dupont, R, Gagnon, M, Boutin, C, Auray-Blais   +3 more
openaire   +2 more sources

How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?

Clinica Chimica Acta, 2010
Fabry disease is characterized by accumulation of glycosphingolipids, such as globotriaosylceramide (Gb(3)), in many tissues and body fluids. A novel plasma biomarker, globotriaosylsphingosine (lyso-Gb(3)), is increased in patients with the disease.
Auray-Blais, Christiane, Ntwari, Aimé, Clarke, Joe T.R., Warnock, David G., Oliveira, João Paulo, Young, Sarah P., Millington, David S., Bichet, Daniel G., Sirrs, Sandra, West, Michael L., Casey, Robin, Hwu, Wuh-Liang, Keutzer, Joan M., Zhang, X. Kate, Gagnon, René   +14 more
openaire   +3 more sources

Lyso-Gb3 determination in classic and late onset Fabry patients

Molecular Genetics and Metabolism, 2023
Paula A. Rozenfeld, Romina Ceci, Agueda Velazco, Emilio Vaena, Andrea N. Crivaro, Juan M. Mucci, Maximiliano E. Ormazabal, Constanza Bondar   +7 more
openaire   +1 more source

Fabry disease: Lyso-Gb3 normalization as a reachable therapeutic goal

Molecular Genetics and Metabolism, 2023
Fernando J. Perretta, Juan M. Politei
openaire   +1 more source

Expanded analysis of Lyso-GB3 analogues and correlation with total Lyso-GB3 and Fabry status in 59 clinical patients

Molecular Genetics and Metabolism, 2018
Brian Netzel, Dimitar Gavrilov, Dietrich Matern, Devin Oglesbee, Kimiyo Raymond, Piero Rinaldo, Silvia Tortorelli, Matthew Schultz   +7 more
openaire   +1 more source

Plasma lyso-Gb3 as a diagnostic marker for Fabry disease

Molecular Genetics and Metabolism, 2018
Sarah Young, Haoyue Zhang, Jian Dai, Patricia McCaw, James Beasley, Denise Peterson, Ashlee Stiles, Marie McDonald, Dwight Koeberl, Deeksha Bali   +9 more
openaire   +1 more source

Effect of lyso-Gb3 on the intestinal microbiota may contribute to gastrointestinal symptoms in Fabry’s disease patients

2020
[Results]: Lyso-Gb3 significantly modified the growth of different bacterial groups of the human intestinal microbiota.
Aguilera-Correa, John-Jairo, Sánchez-Niño, María Dolores, Ortiz, Alberto, Sáez Martínez, Esteban F., Martínez-Cuesta, M. Carmen, Peláez, Carmen, Esteban, Jaime, Requena, Teresa   +7 more
openaire   +1 more source

Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Genetics in Medicine, 2021
Christiane Auray-Blais, Raphaël Schiffmann, Daniel-G Bichet   +2 more
exaly  

Transcriptomics characterization of lyso-Gb3 impact on cultured wild-type human podocytes

Molecular Genetics and Metabolism, 2020
Maria Dolores Sanchez-Niño, Alberto Ortiz   +1 more
openaire   +1 more source

8. How useful is urinary lyso-Gb3 as a biomarker for Fabry disease?

Molecular Genetics and Metabolism, 2010
Christiane Auray-Blais, René Gagnon, David G. Warnock, Sarah P. Young, David S. Millington, Joe T.R. Clarke   +5 more
openaire   +1 more source